Table 2.
Myogenic tone after addition of inhibitors; EC50-values and maximum relaxation for bradykinin in the presence of NS309 (1 µM) and CyPPA (6 µM)
| Treatment | n | Myogenic tone Contraction (Nm−1) | U46619 (0.1 µM) Contraction (Nm−1) |
Bradykinin |
|
|---|---|---|---|---|---|
| EC50 (nM) | Maximum relaxation (%) | ||||
| NS309 | 8 | 0.25 ± 0.06 | 0.9 ± 0.1 | 0.4 ± 0.2 | 97.4 ± 1.1 |
| NS309/ADMA | 7 | 0.63 ± 0.14* | 1.0 ± 0.1 | 8.4 ± 1.3* | 75.7 ± 10.0* |
| NS309/ADMA/oxyhaemoglobin | 8 | 0.56 ± 0.12* | 1.0 ± 0.1 | – | 50.5 ± 8.8* |
| NS309/indomethacin | 8 | 0.39 ± 0.09 | 1.0 ± 0.1 | 1.6 ± 0.7* | 91.0 ± 7.3 |
| NS309/indomethacin/ADMA | 8 | 0.78 ± 0.10* | 0.9 ± 0.1 | – | 54.7 ± 10.0* |
| NS309/indomethacin/ADMA/oxyhaemoglobin | 8 | 0.85 ± 0.12* | 0.9 ± 0.1 | – | 7.3 ± 2.5* |
| CyPPA | 8 | 0.30 ± 0.04 | 1.0 ± 0.1 | 0.5 ± 0.3 | 95.1 ± 2.0 |
| CyPPA/ADMA | 8 | 0.58 ± 0.12* | 1.0 ± 0.1 | 8.7 ± 0.9* | 72.7 ± 9.4* |
| CyPPA/ADMA/oxyhaemoglobin | 8 | 0.66 ± 0.16* | 1.0 ± 0.1 | – | 48.9 ± 10.6* |
| CyPPA/indomethacin | 8 | 0.45 ± 0.09 | 1.0 ± 0.1 | 1.6 ± 0.8* | 91.2 ± 4.0 |
| CyPPA/indomethacin/ADMA | 8 | 0.86 ± 0.12* | 1.0 ± 0.1 | – | 54.4 ± 5.8* |
| CyPPA/indomethacin/ADMA/oxyhaemoglobin | 8 | 0.80 ± 0.13* | 0.9 ± 0.1 | – | 16.0 ± 7.4* |
Mean ± SEM Student's t-test.
*
P < 0.05 from NS309 or CyPPA – indicates that EC50 values could not be calculated, as concentration-response experiments did not reach an asymptotic minimum.
ADMA, asymmetric dimethylarginine; CyPPA, cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methyl-pyrimidin-4- yl]-amine; NS309, 6,7-dichloro-1H-indole-2,3-dione 3-oxime; U46619, 9,11-dideoxy-9a,11a-epoxymethanoprostaglandin F2α.